PROTARA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.79 USD | -0.36% |
|
-4.78% | +48.79% |
Presentation Operator MessageOperator (Operator)Welcome to Proteon Therapeutics Conference Cal...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Companyâs portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
Calendar
07/06/2024
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.79
USD
Average target price
27.8
USD
Spread / Average Target
+896.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +48.79% | 5.74Cr | |
| +9.83% | 12TCr | |
| +10.80% | 10TCr | |
| -10.84% | 2.27TCr | |
| -1.69% | 2.18TCr | |
| -10.23% | 1.82TCr | |
| -41.92% | 1.65TCr | |
| -15.11% | 1.6TCr | |
| +6.62% | 1.41TCr | |
| +17.53% | 1.07TCr |
- Stock Market
- Equities
- TARA Stock
- News Protara Therapeutics, Inc.
- Transcript : Proteon Therapeutics, Inc. - Special Call
